Medtronic ($MDT) lowers earnings expectations again

After a quarter of lower sales and demand, Medtronic ($MDT) has lowered its annual earnings expectation for the second quarter in a row. Its second quarter's profits exceeded analysts' expectations, but the fiscal-year earnings are slated to be $3.38 to $3.44 per share, down from $3.40 to $3.48.

"In the U.S., we continue to see a procedural slowdown as less screenings are occurring and patients are electing to wait longer for their procedures," Medtronic Chief Financial Officer Gary Ellis told analysts, according to Reuters. The company's implantable cardioverter defibrillators can cost up to $35,000, making them a luxury few are willing to purchase during harsher economic times. Ellis also sees patients postponing spinal surgeries, lowering demand for the company's spinal products.

Medtronic has also seen pressure on device prices abroad, particularly in Japan. Shares fell one percent after the lowered expectations were announced.

- check out Reuters' article

Suggested Articles

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.

AstraZeneca is linking up with DeepMatter, a big data firm focused on achieving reproducibility in chemistry, to help improve its compound synthesis.

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.